[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Moore SW, Satgé D, Sasco AJ, Zimmermann A, Plaschkes J: The epidemiology of neonatal tumours. Report of an international working group. Pediatr Surg Int; 2003 Sep;19(7):509-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neonatal tumours occur every 12,500-27,500 live births and comprise 2% of childhood malignancies, but there is little clarity as to their real prevalence, sites of origin and pathological nature as reported series vary.
  • Histologically, teratoma and neuroblastoma remain the two main tumour types encountered with soft tissue sarcoma, renal tumours, CNS tumours and leukaemia being the next most common tumour types identified.
  • Malignant tumours are uncommon in the neonatal period per se and benign tumours may have malignant potential.
  • A particular problem exists in clinical classification, as histological features of malignancy do not always correlate with clinical behaviour.
  • Other tumours may demonstrate local invasiveness, but no metastatic potential, and tumours that are clearly malignant may demonstrate unpredictable or uncertain behaviour.
  • Cytogenetics of neonatal neoplasms appear to differ from neoplasms in older children, thus possibly explaining some of the observed differences in clinical behaviour.
  • Other environmental associations include ionizing radiation, drugs taken during pregnancy, infections, tumours in the mother and environmental exposure.
  • [MeSH-major] Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1984 Jun 8;224(4653):1121-4 [6719137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):937-46 [10895816.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):73-8 [12071533.001]
  • [Cites] Br Med J. 1972 May 27;2(5812):485-8 [4337948.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):513-24 [12028017.001]
  • [Cites] Birth Defects Orig Artic Ser. 1987;23(1):421-31 [3495301.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):603-7 [11107127.001]
  • [Cites] Pediatrics. 1982 Sep;70(3):409-13 [7110816.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):466-8 [10358714.001]
  • [Cites] Am J Med. 1982 Jul;73(1):49-56 [6283885.001]
  • [Cites] Clin Genet. 2000 Sep;58(3):157-61 [11076037.001]
  • [Cites] Lancet. 1976 Sep 4;1(7984):517 [74477.001]
  • [Cites] Pediatr Clin North Am. 1976 Feb;23 (1):233-44 [768885.001]
  • [Cites] Pathology. 1992 Oct;24(4):247-53 [1289765.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):421-8 [8515722.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1981 Fall;3(3):287-96 [7025684.001]
  • [Cites] Am J Dis Child. 1979 Feb;133(2):157-9 [420185.001]
  • [Cites] Pediatr Dev Pathol. 2002 Nov-Dec;5(6):579-86 [12370769.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2223-9 [9649137.001]
  • [Cites] Arch Dis Child. 1987 Jan;62(1):19-23 [3813632.001]
  • [Cites] Am J Perinatol. 2002 Apr;19(3):149-53 [12012290.001]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):391-7 [11984799.001]
  • [Cites] Ugeskr Laeger. 1994 Jan 10;156(2):176-9 [8296406.001]
  • [Cites] Semin Perinatol. 1997 Feb;21(1):102-11 [9190040.001]
  • [Cites] Semin Pediatr Surg. 1997 Aug;6(3):134-40 [9263335.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S8-12 [1323994.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Nature. 1983 Oct 27-Nov 2;305(5937):779-84 [6633649.001]
  • [Cites] J Pediatr Surg. 1995 Apr;30(4):543-5 [7595829.001]
  • [Cites] Am J Dis Child. 1982 Apr;136(4):310-1 [6462054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Dec;70(12):3324-8 [4202843.001]
  • [Cites] Pathologica. 1979 Mar-Apr;71(1012):273-8 [224368.001]
  • [Cites] J Pediatr. 1970 Apr;76(4):585-93 [4316066.001]
  • [Cites] Cancer Lett. 2002 Apr 8;178(1):83-9 [11849745.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] J Comp Pathol. 2002 Aug-Oct;127(2-3):96-105 [12354519.001]
  • [Cites] Int J Epidemiol. 1999 Aug;28(4):631-9 [10480689.001]
  • [Cites] Lancet. 1998 Aug 29;352(9129):682-7 [9728983.001]
  • [Cites] IARC Sci Publ. 1989;(96):403-19 [2680956.001]
  • [Cites] Bull Cancer. 1988;75(4):373-84 [3289644.001]
  • [Cites] Pediatr Neurol. 2001 Mar;24(3):222-4 [11301225.001]
  • [Cites] Arch Fr Pediatr. 1992 Mar;49(3):187-92 [1610275.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1998 May;33(5):290-2 [10682442.001]
  • [Cites] Am J Pathol. 1963 Dec;43:1089-104 [14099453.001]
  • [Cites] Paediatr Perinat Epidemiol. 1998 Jan;12(1):84-117 [9483619.001]
  • [Cites] Clin Genet. 2002 Nov;62(5):345-57 [12431247.001]
  • [Cites] Pathologica. 1989 Nov-Dec;81(1076):651-60 [2635294.001]
  • [Cites] Neurosurgery. 1987 Oct;21(4):557-9 [3683793.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1168-74 [8308685.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):550-8 [11826361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):171-8 [10758320.001]
  • [Cites] Arch Dis Child. 1988 Sep;63(9):1075-8 [3178267.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):606-12 [11169945.001]
  • [Cites] J Pathol. 2002 Aug;197(5):661-7 [12210087.001]
  • [Cites] Folia Med (Plovdiv). 1996;38(3-4):39-43 [9145589.001]
  • [Cites] Br Med J. 1972 Dec 16;4(5841):629-31 [4509453.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):581-91 [2066755.001]
  • [Cites] Pathol Oncol Res. 2001;7(1):67-71 [11349224.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3223-6 [7982186.001]
  • [Cites] Hum Reprod. 2000 Mar;15(3):604-7 [10686204.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1047-53 [11932471.001]
  • [Cites] Pediatr Radiol. 2002 Feb;32(2):106-9 [11819077.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 5;89(3):238-44 [9017004.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):10-6 [12165445.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):109-17 [7388755.001]
  • [Cites] Environ Health Perspect. 2000 Jan;108(1):73-82 [10620527.001]
  • [Cites] Carcinogenesis. 1982;3(1):75-80 [7067040.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] Childs Nerv Syst. 2000 Aug;16(8):501-2 [11007501.001]
  • [Cites] Br J Radiol. 1997 Feb;70:130-9 [9135438.001]
  • [Cites] Pediatr Pathol. 1985;3(2-4):165-216 [3879355.001]
  • [Cites] JAMA. 1978 Sep 29;240(14):1504-5 [210304.001]
  • [Cites] Cancer. 1951 Jul;4(4):890-906 [14859210.001]
  • [Cites] Am J Med Genet. 1998 Jul 7;78(3):207-16 [9677053.001]
  • [Cites] Pediatrics. 1992 Jan;89(1):114-8 [1727993.001]
  • [Cites] Br J Cancer. 1962 Jun;16:177-86 [13908377.001]
  • [Cites] Pediatr Pathol. 1985;4(1-2):163-7 [3006010.001]
  • [Cites] Arch Fr Pediatr. 1967 Aug-Sep;24(7):729-39 [4292870.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):304-10 [9217044.001]
  • [Cites] Arch Dermatol. 1989 Mar;125(3):432-3 [2923454.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S5-7 [1323993.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):772-80 [3395959.001]
  • [Cites] Med Pediatr Oncol. 1989;17(2):101-4 [2704330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10936-41 [10984508.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):313-24 [4347033.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):63-70 [8646744.001]
  • [Cites] Helv Paediatr Acta. 1981 Sep;36(4):377-82 [6268574.001]
  • [Cites] Hum Reprod. 1999 May;14 (5):1324-7 [10325286.001]
  • [Cites] Am J Dis Child. 1969 Feb;117(2):186-9 [4236770.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):157-9 [11464873.001]
  • [Cites] FASEB J. 1993 Jul;7(10):886-95 [8393819.001]
  • [Cites] Pediatrics. 1990 Nov;86(5):765-73 [2152340.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):498-504 [10698519.001]
  • [Cites] Pediatr Int. 2000 Oct;42(5):492-8 [11059537.001]
  • [Cites] N Engl J Med. 1985 Jun 13;312(24):1569-70 [4000188.001]
  • [Cites] Med Pediatr Oncol. 2002 Nov;39(5):508-9 [12228908.001]
  • [Cites] Pediatr Surg Int. 2002 Sep;18(5-6):306-9 [12415344.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1981 Fall;3(3):279-85 [6269454.001]
  • [Cites] Pediatr Pathol. 1991 Sep-Oct;11(5):781-9 [1745644.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Spring;13(1):3-7 [2029075.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):37-46 [11272900.001]
  • (PMID = 14523568.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 128
  •  go-up   go-down


2. Relander T, Cavallin-Ståhl E, Garwicz S, Olsson AM, Willén M: Gonadal and sexual function in men treated for childhood cancer. Med Pediatr Oncol; 2000 Jul;35(1):52-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadal and sexual function in men treated for childhood cancer.
  • BACKGROUND: Insofar as a majority of children with malignant diseases are cured, the late effects of treatment are of major importance.
  • PROCEDURE: A retrospective study was conducted of gonadal and sexual function of 77 adult male survivors of childhood malignancies treated and cured at a single center from 1970 to 1989 and followed for a median of 13 years.
  • RESULTS: One-third of the patients were treated for hematological malignancies, one-third for CNS tumors, and one-third for other malignancies.
  • Eleven patients required androgen substitution after treatment for tumors of the pituitary-hypothalamic region or acute lymphoblastic leukemia including testicular irradiation and/or orchiectomy.
  • CONCLUSIONS: Patients treated for tumors in the hypothalamic-pituitary region or treated with testicular irradiation or with high doses of alkylating agents had severe gonadal and sexual dysfunction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasms / drug therapy. Neoplasms / radiotherapy. Sexuality. Testis / drug effects. Testis / radiation effects
  • [MeSH-minor] Adolescent. Adult. Androgens / therapeutic use. Body Constitution. Gonadal Steroid Hormones / blood. Humans. Interviews as Topic. Male. Registries. Retrospective Studies. Sperm Count / drug effects. Sperm Count / radiation effects. Surveys and Questionnaires. Survivors. Sweden. Testicular Diseases / etiology. Testicular Diseases / physiopathology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10881008.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Androgens; 0 / Gonadal Steroid Hormones
  •  go-up   go-down


3. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP, Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B: Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J; 2007 Aug 15;406(1):57-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel role for insulin as an autocrine growth factor for malignant brain tumour cells.
  • AT/RTs (atypical teratoid/rhabdoid tumours) of the CNS (central nervous system) are childhood malignancies associated with poor survival rates due to resistance to conventional treatments such as chemotherapy.
  • We characterized a panel of human AT/RT and MRT (malignant rhabdoid tumour) cell lines for expression of RTKs (receptor tyrosine kinases) and their involvement in tumour growth and survival.
  • Pharmacological inhibitors, neutralizing antibodies, or RNAi (RNA interference) targeting the IR impaired the growth of AT/RT cell lines and induced apoptosis.
  • Experiments using RNAi and isoform-specific pharmacological inhibitors established a key role for the class I(A) PI3K p110alpha isoform in AT/RT cell growth and insulin signalling.
  • Taken together, our results reveal a novel role for autocrine signalling by insulin and the IR in growth and survival of malignant human CNS tumour cells via the PI3K/Akt pathway.
  • [MeSH-major] Autocrine Communication. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Growth Substances / metabolism. Insulin / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Child, Preschool. Chromosomal Proteins, Non-Histone / metabolism. Culture Media, Serum-Free. DNA-Binding Proteins / metabolism. Down-Regulation / drug effects. Down-Regulation / genetics. Enzyme Activation / drug effects. Female. Humans. Infant. Isoenzymes / metabolism. Male. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. RNA, Small Interfering / metabolism. Receptor, IGF Type 1 / metabolism. Receptor, Insulin / genetics. Receptor, Insulin / metabolism. Signal Transduction / drug effects. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2661-74 [16537910.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10123-7 [16287993.001]
  • [Cites] Cell. 2006 May 19;125(4):733-47 [16647110.001]
  • [Cites] Biosci Rep. 2006 Feb;26(1):7-17 [16779663.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1761-6 [16823473.001]
  • [Cites] Drug News Perspect. 2006 Jun;19(5):261-72 [16941048.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2527-38 [16988940.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1581-9 [17446062.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Annu Rev Biochem. 2001;70:247-79 [11395408.001]
  • [Cites] Annu Rev Biochem. 2001;70:535-602 [11395417.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5975-88 [12138206.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3461-7 [12429635.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2647-54 [12594293.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):778-85 [14710358.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Nature. 2004 Mar 25;428(6981):427-31 [15042091.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):505-18 [15229476.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5940-8 [15355927.001]
  • [Cites] Biochem J. 1990 Sep 1;270(2):397-400 [2205203.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13488-97 [1618850.001]
  • [Cites] Annu Rev Biochem. 1992;61:307-30 [1323236.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4251-9 [7901001.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1459-67 [7534700.001]
  • [Cites] Endocr Rev. 1995 Feb;16(1):3-34 [7758431.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2117-30 [8804307.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5370-82 [8895581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3777-82 [9108054.001]
  • [Cites] Trends Biochem Sci. 1997 Jul;22(7):267-72 [9255069.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] Hum Mol Genet. 1999 Dec;8(13):2359-68 [10556283.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2759-63 [10914721.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800 [11095756.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jan-Feb;4(1):23-31 [11200487.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3598-603 [11313485.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):309-13 [16195799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50 [16301525.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):722-34 [16302003.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1111-7 [16186793.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):465-8 [16450000.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3278-88 [10207053.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2471-9 [10229198.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):379-85 [10229502.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):552-7 [15550513.001]
  • [Cites] J Pathol. 2005 Jan;205(2):145-53 [15641016.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] Nat Med. 2005 May;11(5):507-14 [15834429.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):421-39 [15936977.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1432-40 [15878979.001]
  • [Cites] Nature. 2006 May 18;441(7091):366-70 [16625210.001]
  • (PMID = 17506723.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Culture Media, Serum-Free; 0 / DNA-Binding Proteins; 0 / Growth Substances; 0 / Insulin; 0 / Isoenzymes; 0 / RNA, Small Interfering; 0 / SMARCB1 protein, human; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1948991
  •  go-up   go-down


Advertisement
4. Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D, Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee: Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer; 2010 Jan;46(1):120-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.
  • BACKGROUND: Radiotherapy is an effective adjuvant treatment for brain tumours arising in very young children, but it has the potential to damage the child's developing nervous system at a crucial time - with a resultant reduction in IQ leading to cognitive impairment, associated endocrinopathy and risk of second malignancy.
  • We aimed to assess the role of a primary chemotherapy strategy in avoiding or delaying radiotherapy in children younger than 3 years with malignant brain tumours other than ependymoma, the results of which have already been published.
  • METHODS: Ninety-seven children were enrolled between March 1993 and July 2003 and, following diagnostic review, comprised: medulloblastoma (n=31), astrocytoma (26), choroid plexus carcinoma [CPC] (15), CNS PNET (11), atypical teratoid/rhabdoid tumours [AT/RT] (6) and ineligible (6).
  • FINDINGS: Over all diagnostic groups the cumulative progression rate was 80.9% at 5 years while the corresponding need-for-radiotherapy rate for progression was 54.6%, but both rates varied by tumour type.
  • This treatment strategy was less effective for AT/RT with 3-year OS of 16.7% (CI: 0.8-51.7) and CNS PNET with 1-year OS of 9.1% (CI: 0.5-33.3).
  • INTERPRETATION: The outcome for very young children with brain tumours is dictated by degree of surgical resection and histological tumour type and underlying biology as an indicator of treatment sensitivity.
  • Desmoplastic/nodular sub-type of medulloblastoma has a better prognosis than classic histology, despite traditional adverse clinical features of metastatic disease and incomplete surgical resection.
  • This study highlights the differing therapeutic challenges presented by the malignant brain tumours of early childhood, the importance of surgical approaches and the need to explore individualised brain sparing approaches to the range of malignant brain tumours that present in early childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child, Preschool. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / radiotherapy. Choroid Plexus Neoplasms / surgery. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / radiotherapy. Neuroectodermal Tumors, Primitive / surgery. Radiotherapy, Adjuvant / methods. Survival Analysis. Teratoma / drug therapy. Teratoma / radiotherapy. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818598.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


5. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • VNP40101M, or 1,2-bis(methylsulfonyl)-1-(2-choloroethyl)-2-(methylamino)carbonylhydrazine (Cloretazine), is a bifunctional prodrug that belongs to a class of DNA-modifying agents-the sulfonylhydrazines-that has been synthesized and been shown to have activity against a wide spectrum of xenografts.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Delayed toxicity was seen more than 60 days after treatment, with 23 deaths in 100 treated animals, despite a median weight loss of only 0.06%.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


6. Klesse LJ, Bowers DC: Childhood medulloblastoma: current status of biology and treatment. CNS Drugs; 2010 Apr;24(4):285-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood medulloblastoma: current status of biology and treatment.
  • Medulloblastoma, a primitive neuro-ectodermal tumour that arises in the posterior fossa, is the most common malignant brain tumour occurring in childhood.
  • In this review, we describe the current understanding of the basic biology of medulloblastoma and report on the current active chemotherapeutic agents utilized in medulloblastoma therapy.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Cerebellar Neoplasms / therapy. Medulloblastoma / metabolism. Medulloblastoma / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Child. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):330-6 [2153766.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):573-80 [16054568.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):705-12 [11531256.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1922-7 [8656261.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):263-7 [17453147.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Neurologist. 2004 Nov;10(6):293-310 [15518596.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Orphanet J Rare Dis. 2008 Nov 25;3:32 [19032739.001]
  • [Cites] BMC Cancer. 2002 Dec 2;2:33 [12460454.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):140-8 [12517790.001]
  • [Cites] Nat Med. 2003 Aug;9(8):1033-8 [12872164.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):77-81 [10738305.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23 (31):7951-7 [16258095.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1263-6 [15467454.001]
  • [Cites] Cancer Res. 1981 Apr;41(4):1466-8 [6260340.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):376-85 [12946027.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3357-65 [15310781.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5482-93 [15328187.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Klin Padiatr. 2007 Nov-Dec;219(6):312-7 [18050040.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28341-4 [10884376.001]
  • [Cites] Ann Neurol. 1990 Dec;28(6):823-8 [2178331.001]
  • [Cites] Cancer Lett. 2006 Jan 18;231(2):262-9 [16399227.001]
  • [Cites] Mod Pathol. 1990 Mar;3(2):164-70 [2109316.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4733-40 [16000568.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):552-60 [11900240.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):273-8 [16195803.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2291-7 [17019740.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):271-9 [12187960.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4881-7 [15611503.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):649-53 [3258630.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):319-34 [16942675.001]
  • [Cites] Pediatrics. 1967 May;39(5):761-3 [6026877.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1768-76 [18339857.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):44-51 [10564585.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2821-7 [18539960.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):874-80 [8756384.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Curr Top Med Chem. 2008;8(1):38-46 [18220931.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8 [15249678.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12 ):1173-8 [19726761.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):77-82 [9588920.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5428-37 [14500378.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12867-71 [7809137.001]
  • [Cites] Annu Rev Neurosci. 2001;24:385-428 [11283316.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2478-85 [9667267.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7267-73 [15378086.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):338-48 [17975007.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):243-51 [18688572.001]
  • [Cites] Pediatr Neurosurg. 2003 Jul;39(2):60-7 [12845195.001]
  • [Cites] Curr Biol. 1999 Dec 2;9(23):1415-8 [10607566.001]
  • [Cites] Cell Cycle. 2006 Nov;5(22):2666-70 [17172831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):543-7 [12062595.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):441-9 [15198123.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):540-4 [11958658.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2425-33 [11489822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):599-605 [11849779.001]
  • [Cites] J Endocrinol. 2007 Sep;194(3):459-74 [17761886.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5579-82 [17575119.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Mol Phylogenet Evol. 1999 Mar;11(2):308-19 [10191075.001]
  • [Cites] Expert Rev Neurother. 2008 Nov;8(11):1611-3 [18986229.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):384-92 [17704359.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7152-60 [16192599.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):2996-3003 [16996732.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):577-84 [10675492.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):563-7 [9324345.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):188-96 [7838041.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Apr;59(4):333-7 [10759189.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93 [10936465.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):190-6 [7623728.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Nov-Dec;11(6):1100-3 [2124036.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2755-62 [8402500.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4975-8 [15958535.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1169-75 [18293379.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):222-8 [9440746.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] Eur J Paediatr Neurol. 2003;7(2):53-66 [12697428.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):209-18 [15050952.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Pediatr Blood Cancer. 2017 Jun;64(6): [28000417.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2696-704 [11352962.001]
  • [Cites] Acta Neuropathol. 1987;73(2):115-23 [3604579.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] Arch Dis Child. 1996 Mar;74(3):219-23 [8787426.001]
  • [Cites] Lab Invest. 2008 Feb;88(2):98-111 [18059365.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3272-80 [9242460.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8588-96 [16314621.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):87-98 [8699230.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):480-7 [11208842.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):820-5 [2585072.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1815-20 [11920545.001]
  • [Cites] J Neurooncol. 2008 Apr;87(2):133-41 [18060600.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7794-800 [15520185.001]
  • (PMID = 20297854.001).
  • [ISSN] 1179-1934
  • [Journal-full-title] CNS drugs
  • [ISO-abbreviation] CNS Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 134
  •  go-up   go-down


7. Moppett J, Oakhill A, Duncan AW: Second malignancies in children: the usual suspects? Eur J Radiol; 2001 Feb;37(2):95-108
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this article is to provide an up to date review of second malignant neoplasms (SMN's) following treatment for childhood cancer, referring to their incidence, the role of genetic factors, and how the primary malignancy and treatment received influence the type, site and prognosis of SMN's.
  • The important second malignancies will be highlighted, including tumours of the CNS and thyroid, osteosarcoma, secondary acute myeloid leukaemia and melanoma.
  • Finally, the important but different roles of causal agents, in particular chemotherapy and radiotherapy are highlighted.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Imaging. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Osteosarcoma / diagnosis. Skin Neoplasms / diagnosis. Thyroid Neoplasms / diagnosis


8. Zimmerman MA, Goumnerova LC, Proctor M, Scott RM, Marcus K, Pomeroy SL, Turner CD, Chi SN, Chordas C, Kieran MW: Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol; 2005 Mar;72(1):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor.
  • Atypical teratoid/rhabdoid tumors (AT/RT) are highly malignant lesions of childhood that carry a very poor prognosis.
  • AT/RT can occur in the central nervous system (CNS AT/RT) and disease in this location carries an even worse prognosis with a median survival of 7 months.
  • In spite of multiple treatment regimens consisting of maximal surgical resection (including second look surgery), radiation therapy (focal and craniospinal), and multi-agent intravenous, oral and intrathecal chemotherapy, with or without high-dose therapy and stem cell rescue, only seven long-term survivors of CNS AT/RT have been reported, all in patients with newly diagnosed disease.
  • We now report on four children, two with newly diagnosed CNS AT/RT and two with progressive disease after multi-agent chemotherapy who are long term survivors (median follow-up of 37 months) using a combination of surgery, radiation therapy, and intensive chemotherapy.
  • The chemotherapy component was modified from the Intergroup Rhabdomyosarcoma Study Group (IRS III) parameningeal protocol as three of the seven reported survivors in the literature were treated using this type of therapy.
  • More importantly, we report on the first two survivors after relapse with multi-agent intravenous and intrathecal chemotherapy treated with this modified regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(4):393-7 [3125680.001]
  • [Cites] Childs Nerv Syst. 1993 Jun;9(3):185-90; discussion 190 [8397069.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):31-7 [10738300.001]
  • [Cites] Arch Ophthalmol. 1967 Dec;78(6):709-13 [4294312.001]
  • [Cites] Surg Neurol. 1992 May;37(5):410-4 [1631771.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):37-40 [7459813.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):418-21 [9298280.001]
  • [Cites] Surv Ophthalmol. 1994 Jan-Feb;38(4):365-70 [8160109.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Semin Diagn Pathol. 1986 May;3(2):151-63 [3616219.001]
  • [Cites] J Neurooncol. 1999 May;43(1):63-70 [10448873.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):310-7 [2056976.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):710-4 [2213160.001]
  • [Cites] Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1989 Sep-Oct;30(5):316-22 [2484056.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2000 May;48(1):41-5 [11026695.001]
  • [Cites] Can J Neurol Sci. 1994 Aug;21(3):273-7 [8000986.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):107-15 [8427070.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):429-34 [8211663.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Jun;29(3):254-61 [12787322.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurooncol. 1995;25(3):193-203 [8592169.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1727-8 [7502982.001]
  • [Cites] Pediatr Neurol. 1995 Jul;13(1):65-8 [7575853.001]
  • [Cites] Acta Neuropathol. 1996;91(6):578-86 [8781656.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):723-6 [12378033.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):219-25 [12675315.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):275-7 [12709762.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):389-91 [10219345.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2058-61 [2004323.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):214-22 [7619723.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):23-8 [8191632.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):53-6 [11763423.001]
  • [Cites] Neurology. 1991 Nov;41(11):1847-8 [1944923.001]
  • [Cites] Clin Neuropathol. 1991 Jan-Feb;10(1):1-10 [2015720.001]
  • [Cites] Childs Nerv Syst. 1987;3(6):379-81 [3450389.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Comput Assist Tomogr. 1990 May-Jun;14 (3):461-3 [2335617.001]
  • [Cites] Pediatr Neurosurg. 1994;21(4):232-6 [7865408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800 [11095756.001]
  • [Cites] Pediatr Pathol. 1989;9(3):307-19 [2546137.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):244-8 [12682757.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] Postgrad Med J. 1998 Jun;74(872):369-70 [9799897.001]
  • [Cites] Childs Nerv Syst. 2000 Apr;16(4):228-34 [10855521.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • (PMID = 15803379.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


9. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS: Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol; 2001 Sep;48(3):250-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
  • PURPOSE: The in vivo antitumor activity of a novel topoisomerase I inhibitor, J-107088, was tested in athymic nude mice bearing subcutaneous or intracranial pediatric and adult malignant CNS tumor-derived xenografts.
  • METHODS: J-107088 was administered to animals on days 1-5 and 8-12 via intraperitoneal injection at a dose of 54 mg/kg (162 mg/m2) per day in 10% dimethyl sulfoxide in 0.9% saline.
  • The xenografts evaluated were derived from a childhood glioblastoma multiforme (D-456 MG), a childhood medulloblastoma (D-341 MED), an adult anaplastic astrocytoma (D-54 MG), an adult glioblastoma multiforme (D-245 MG), and a procarbazine-resistant subline of D-245 MG [D-245 MG (PR)].
  • CONCLUSION: These results indicate that J-107088 may be active in the treatment of childhood and adult malignant brain tumors and provide the rationale for initiation of clinical trials with this agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Carbazoles / therapeutic use. Enzyme Inhibitors / therapeutic use. Glioma / drug therapy. Glucosides / therapeutic use. Indoles. Topoisomerase I Inhibitors
  • [MeSH-minor] Adult. Animals. Child. Female. Humans. Injections, Intraperitoneal. Injections, Subcutaneous. Male. Mice. Mice, Nude. Neoplasm Transplantation. Survival Rate. Transplantation, Heterologous. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11592348.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 2RO1-NS30245-12; United States / NINDS NIH HHS / NS / 5P50-NS-20023-17; United States / NCI NIH HHS / CA / CA11898; etc
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Enzyme Inhibitors; 0 / Glucosides; 0 / Indoles; 0 / Topoisomerase I Inhibitors; 1V8X590XDP / edotecarin
  •  go-up   go-down


10. Moppett J, Oakhill A, Duncan AW: Second malignancies in children: the usual suspects? Eur J Radiol; 2001 Jun;38(3):235-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this article is to provide an up to date review of second malignant neoplasms (SMN's) following treatment for childhood cancer, referring to their incidence, the role of genetic factors, and how the primary malignancy and treatment received influence the type, site and prognosis of SMN's.
  • The important second malignancies will be highlighted, including tumours of the CNS and thyroid, osteosarcoma, secondary acute myeloid leukaemia and melanoma.
  • Finally, the important but different roles of causal agents, in particular chemotherapy and radiotherapy are highlighted.
  • [MeSH-major] Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Bone Neoplasms / etiology. Central Nervous System Neoplasms / etiology. Child. Female. Genetic Predisposition to Disease. Hodgkin Disease / therapy. Humans. Male. Melanoma / etiology. Neoplasms, Radiation-Induced. Osteosarcoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiotherapy / adverse effects. Retinal Neoplasms / genetics. Retinal Neoplasms / therapy. Retinoblastoma / genetics. Retinoblastoma / therapy. Risk Factors. Thyroid Neoplasms / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Eur J Radiol. 2001 Feb;37(2):95-108 [11223476.001]
  • (PMID = 11399379.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Marchetti D, Mrak RE, Paulsen DD, Sinnappah-Kang ND: Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion. J Exp Clin Cancer Res; 2007 Mar;26(1):5-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma (MB) is the most common malignant brain tumor of childhood.
  • Neurotrophins (NT) comprise a family of structurally and functionally related neurotrophic factors that are critical for central nervous system (CNS) development with nerve growth factor (NGF) being the prototypic NT.
  • NT acts through two groups of structurally unrelated neurotrophin receptors (NTR): a family of receptor tyrosine kinases (Trks, mainly TrkA, TrkB, and TrkC) and a tumor necrosis factor receptor (TNFR)-like molecule called p75NTR TrkC expression is a good prognostic indicator for MB.
  • Importantly, little is known about the biological functions of p75 in primitive neuroectodermal tumors such as MB.
  • In contrast, NT-regulated heparanase (HPSE) is a unique extracellular matrix-degrading enzyme known to be associated with tumor progression in a wide variety of cancers.
  • Taken together, our data provide evidence that HPSE functionality, in a context linked to TrkC and p75NTR activation, may play critical roles in medulloblastoma tumor invasion and progression.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Glucuronidase / metabolism. Medulloblastoma / metabolism. Meningeal Neoplasms / metabolism. Receptors, Nerve Growth Factor / metabolism
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Infant. Male. NF-kappa B / metabolism. Neoplasm Invasiveness. Nerve Tissue Proteins / metabolism. Neurotrophin 3 / metabolism. Neurotrophin 3 / pharmacology. Phosphorylation. Prognosis. Receptor, trkC / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550129.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA086832; United States / NCI NIH HHS / CA / CA103955
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Neurotrophin 3; 0 / Receptors, Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkC; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


12. Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M: Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood; 2000 May 1;95(9):2770-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.
  • Secondary neoplasms (SNs) represent serious late complications after successful treatment of malignant diseases.
  • To evaluate the rate and type of SNs after Berlin-Frankfurt-Münster (BFM) treatment in children with acute lymphoblastic leukemia (ALL), we analyzed the data from the BFM database and the German Childhood Cancer Registry (GCCR).
  • By December 1997, 52 SNs were documented, including 16 acute myeloid leukemias (AMLs), 13 neoplasms of the central nervous system (CNS), and 23 other neoplasms.
  • Compared with the expected numbers estimated from incidence rates derived from the GCCR, this represented a 14-fold increase for all cancers and a 19-fold increase for CNS tumors.
  • The development of secondary AML was not associated with the use of any specific cytotoxic agent.
  • Considering the high-survival rate of this large unselected ALL cohort, the risk of SN is relatively low, though higher, especially after cranial irradiation, than in the general population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Child. Child, Preschool. Combined Modality Therapy. Databases as Topic. Disease-Free Survival. Female. Follow-Up Studies. Germany. Humans. Infant. Infant, Newborn. Male. Registries. Retrospective Studies. Risk Factors. Survival Analysis






Advertisement